Subcutaneous injection
TB-500
A synthetic compound studied for healing support.
TB-500 is a synthetic version of a fragment of thymosin beta-4, studied for its potential role in cell migration and healing. It has not been through the clinical trials the FDA requires to approve a drug. rhome's TB-500 is compounded by a licensed pharmacy from your clinician's prescription.
From $179 per month1not FDA approved
Compounded under a temporary federal policy (HHS, October 28, 2026) while the FDA decides whether to add it to its compounding list. That is not FDA approval, and the policy can change.
Your rhythm
On the schedule your clinician sets.
What to expect
Living with TB-500.
- 01
Clinician-set dose and schedule
- 02
Compounded by licensed U.S. pharmacies
- 03
One active ingredient per prescription, never a blend
- 04
Adjust or cancel any time
Questions
Straight answers.
No. On October 28, 2026, the U.S. Department of Health and Human Services issued an interim enforcement-discretion policy: it does not intend to act against licensed pharmacies that compound this substance from a patient-specific prescription, under set conditions, while the FDA finishes its rulemaking. That is not FDA approval. The substance has not been evaluated by the FDA for safety, effectiveness, or quality the way an approved drug is, and it has not been added to the FDA's 503A bulk drug list; an FDA advisory committee recommended adding it in July 2026 and the FDA has not decided. The policy is temporary and can change.
No. Under the federal interim policy each compounded product holds a single active ingredient, so rhome does not offer blends. Whether more than one treatment is appropriate for you is your clinician's decision.
Then a box at the door.
Your first box, in your treatment’s colour, with a card on top with your name on it.